New drug combo shows promise for Hard-to-Treat lung cancer
NCT ID NCT07410611
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called befotertinib combined with radiation therapy for people with advanced non-small cell lung cancer that has an EGFR mutation and has spread to only a few spots. The goal is to see if this combination can delay cancer growth. About 84 participants will receive the treatment, and doctors will use a blood test to monitor the cancer's DNA and guide care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE TESTED POSITIVE FOR EGFR MUTATIONS CONFIRMED BY HISTOPATHOLOGICAL EXAMINATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China